The companies have been looking for ways to gain an edge through deals with the firms that control drug benefits for Americans, discounts for cash-pay customers and, more recently, new direct-to-employer plans
Patients and providers still sought these therapies, but without a legal, regulated option, a gray market began to fill the gap, one characterized by unverified sources, inconsistent quality, and little to no pharmacist oversight.[5] In that environment, the very risks regulators aim to mitigate can become more difficult to control
"These conditions can manifest in young individuals without any prior symptoms
For those keen on managing their blood sugar and weight naturally, understanding and boosting GLP-1 levels can be a game-changer
While semaglutide was originally developed for type 2 diabetes, it is effective for weight loss in non-diabetic patients
Invest 121 , 35893597 (2011)